Analyzing MediciNova (NASDAQ:MNOV) and Palisade Bio (NASDAQ:PALI)

Palisade Bio (NASDAQ:PALI) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Insider and Institutional Ownership

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Palisade Bio and MediciNova”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250,000.00	1,411.59	-$16.78 million	($0.48)	-4.22
MediciNova	$410,000.00	209.49	-$12.00 million	($0.21)	-8.31

MediciNova has higher revenue and earnings than Palisade Bio. MediciNova is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Palisade Bio and MediciNova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
MediciNova	-1,168.70%	-26.51%	-24.39%

Volatility and Risk

Palisade Bio has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Palisade Bio and MediciNova, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1	0	7	2	3.00
MediciNova	1	1	3	1	2.67

Palisade Bio presently has a consensus target price of $9.00, suggesting a potential upside of 344.44%. MediciNova has a consensus target price of $8.33, suggesting a potential upside of 377.55%. Given MediciNova’s higher probable upside, analysts clearly believe MediciNova is more favorable than Palisade Bio.

Summary

Palisade Bio beats MediciNova on 8 of the 15 factors compared between the two stocks.

About Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

About MediciNova

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.